Purpose: Metformin (MF) acts as a tumour-suppressor in renal cell carcinoma (RCC) by inhibiting the AKT/mTOR pathway via AMPK activation. Here, we explore the influence of miR-21 and its target gene PTEN on MF effects in CAKI-1 and CAKI-2 cells. Methods: Proliferation assays (MTS) and qRT-PCR after transient transfection with pre- and anti-miR-21 and MF treatment were conducted. AMPK-dependency was assessed via transfection of siAMPK. The expression of PTEN, AKT and miR-21 after transient pre-miR-21 transfection and MF treatment was analysed. Results: We demonstrate that CAKI-1 cells, which were found to be less sensitive towards MF, showed a significant higher miR-21 and lower PTEN expression than CAKI-2. This was confirmed in a primary RCC collective (n = 28): miR-21 and PTEN expression correlated negatively. MF treatment lowered miR-21 AMPK-dependently and increased PTEN expression in the cell lines. Ectopic miR-21 regulation modulated MF sensitivity. Western blot analysis showed that pre-miR-21 transfection and MF treatment regulated PTEN expression with impact on pAKT levels in the cells. Conclusions: We show that differing MF sensitivity in RCC cells is associated with and mediated through the regulation of miR-21/PTEN expression with an impact on subsequent AKT signalling. This provides imaginable clinical implications regarding MF therapy of RCC patients for the future.

Keywords:
microRNA, miRNA, miR-21, PTEN, Metformin, Renal cell carcinoma, Kidney cancer, Biomarker
1.
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554.
2.
Li W, Ma W, Zhong H, Liu W, Sun Q: Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med 2014;7:389-392.
3.
Hadad SM, Hardie DG, Appleyard V, Thompson AM: Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014;16:746-752.
4.
Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC: The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014;111:628-636.
5.
Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT: Metformin use and prostate cancer risk. Eur Urol 2014;66:1012-1020.
6.
Psutka SP, Boorjian SA, Lohse CM, Stewart SB, Tollefson MK, Cheville JC, Leibovich BC, Thompson RH: The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol 2015;33:67.e15-e23.
7.
Li M, Liu J, Hu WL, Jia CH, Li HY, Wen ZH, et al: [Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms]. Nan Fang Yi Ke Da Xue Xue Bao 2011;31:1504-1508.
8.
Liu J, Li M, Song B, Jia C, Zhang L, Bai X, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013;31:264-270.
9.
Iliopoulos D, Hirsch HA, Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71:3196-3201.
10.
MacKenzie MJ, Ernst S, Johnson C, Winquist E: A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs 2012;30:647-652.
11.
Woodard J, Joshi S, Viollet B, Hay N, Platanias LC: AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010;10:1168-1177.
12.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
13.
Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-3586.
14.
Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA: mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009;11:455-459.
15.
Kuru TH, Huber J, Hatiboglu G, Wagener N, Pahernik S, Hadaschik B, Hohenfellner M: Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response. Urol Int 2011;86:256-260.
16.
Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al: Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011;10:1144-1151.
17.
Li W, Yuan Y, Huang L, Qiao M, Zhang Y: Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012;96:187-195.
18.
Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, et al: Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 2012;3:865.
19.
Yang FQ, Wang JJ, Yan JS, Huang JH, Li W, Che JP, Wang GC, Liu M, Zheng JH: Metformin inhibits cell growth by upregulating microRNA-26a in renal cancer cells. Int J Clin Exp Med 2014;7:3289-3296.
20.
Du T, Zamore PD: microPrimer: the biogenesis and function of microRNA. Development 2005;132:4645-4652.
21.
Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009;13:3918-3928.
22.
Vergho DC, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, Spahn M, Löser A, Kocot A, Riedmiller H, Kneitz B: Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PLoS One 2014;9:e109877.
23.
Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, et al: Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer 2014;14:25.
24.
Zaman MS, Shahryari V, Deng G, Thamminana S, Saini S, Majid S, et al: Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 2012;7:e31060.
25.
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-2360.
26.
Zhang W, Bai W, et al: MiR-21 suppresses the anticancer activities of curcumin by targeting PTEN gene in human non-small cell lung cancer A549 cells. Clin Transl Oncol 2014;16:708-713.
27.
Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, et al: The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012;14:385-392.
28.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-658.
29.
Zhang A, Liu Y, Shen Y, Xu Y, Li X: miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology 2011;78:474.e13-e19.
30.
Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, et al: MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 2012;29:920-926.
31.
Nangia-Makker P, Yu Y, Vasudevan A, Farhana L, Rajendra SG, Levi E, Majumdar AP: Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 2014;9:e84369.
32.
Li X, Xin S, He Z, Che X, Wang J, Xiao X, Song X: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 2014;33:1631-1642.
33.
Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Schrader AJ: Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - a multicentre study. Eur J Cancer 2012;48:2347-2352.
34.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, et al: Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria. Cancer 2013;119:2999-3006.
35.
Kondo K, Yao M, Kobayashi K, Ota S, Yoshida M, Kaneko S, et al: PTEN/MMAC1/TEP1 mutations in human primary renal‐cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001;91:219-224.
36.
Brenner W, Färber G, Herget T, Lehr HA, Hengstler JG, Thüroff JW: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002;99:53-57.
37.
Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, et al: Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 2008;80:372-377.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.